Table 1.
Test and validation cohort characteristics.
| Variable | Test cohort (n = 1,359) |
Validation cohort (n = 1,085) |
p value |
|---|---|---|---|
| Age, years (±SD) | 58 ± 8 | 58 ± 8 | 0.99 |
| Male sex, n (%) | 1,124 (82.7) | 844 (77.8) | 0.002 |
| Median waiting list (IQR), months | 6.1 (3.0–11.0) | 4.9 (1.7–10.0) | <0.0001 |
| Aetiology of liver disease, n (%) | |||
| Viral | 786 (57.8) | 610 (56.2) | <0.0001 |
| Alcohol | 426 (31.3) | 183 (16.9) | |
| Other | 147 (10.8) | 292 (26.9) | |
| HBV, n (%) | 94 (6.9) | 149 (13.7) | <0.0001 |
| HCV, n (%) |
696 (51.2) |
466 (42.9) |
<0.0001 |
| Data at listing | |||
| AFP (ng/ml) | |||
| ≤100 ng/ml, n (%) | 1,212 (89.2) | 877 (81.1) | <0.0001 |
| 101–1,000 ng/ml, n (%) | 129 (9.5) | 165 (15.3) | |
| >1,000 ng/ml, n (%) | 18 (1.3) | 39 (3.6) | |
| Within the Milan criteria, n (%) | 1,039 (76.4) | 939 (86.5) | <0.0001 |
| AFP score | |||
| ≤2 points, n (%) | 1,221 (89.9) | 942 (87.1) | 0.032 |
| >2 points, n (%) | 137 (10.1) | 139 (12.9) | |
| Bridging therapy before LT∗, n (%) |
931 (68.5) |
782 (72.1) |
0.055 |
| Data at last tumour reassessment | |||
| AFP (ng/ml) | |||
| ≤100 ng/ml, n (%) | 1,191 (88.0) | 893 (82.8) | 0.001 |
| 101–1,000 ng/ml, n (%) | 136 (10.0) | 147 (13.6) | |
| >1,000 ng/ml, n (%) | 27 (2.0) | 39 (3.6) | |
| Within the Milan criteria, n (%) | 234 (80.1) | 931 (85.8) | 0.020 |
| AFP score | |||
| ≤2 points, n (%) | 250 (87.1) | 953 (88.1) | 0.66 |
| >2 points, n (%) | 37 (12.9) | 129 (11.9) | |
Test cohort (European cohort). Validation cohort (Latin American cohort).
AFP, alpha-foetoprotein; LT, liver transplantation.
∗
Refer to Table S8.